載入...
Tumefactive demyelination presenting during bevacizumab treatment
We report the emergence of tumefactive demyelination during treatment with intravitreal bevacizumab (Avastin). This is of particular significance given that bevacizumab is currently being assessed as a potential treatment option for neuromyelitis optica, another demyelinating condition.
Na minha lista:
| 發表在: | BMJ Case Rep |
|---|---|
| Main Authors: | , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BMJ Publishing Group
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4691864/ https://ncbi.nlm.nih.gov/pubmed/26677151 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2015-212173 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|